Search for a trial

The development of a thirst provocation test using the AVP receptor antagonist Tolvaptan for quantification of thirst sensation in various patient groups (obese patients with and without a history of bariatric surgery, patients with congestive heart failure and patients with cranial diabetes insipidus as compared to healthy controls) and genotyping of the AVP receptor 2.

We aim to investigate thirst in the above mentioned patient groups, applying a Visual Analogue Scale (VAS) and, where ethically acceptable, a new thirst provocation test which we will develop in a group of healthy probands. Using these tools, we aim…